![](/images/graphics-bg.png)
Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
المؤلفون المشاركون
Yang, Jiali
Liu, Xiaoming
Sui, Hongshu
Ma, Ningxia
Wang, Ying
Li, Hui
Su, Yanping
المصدر
Journal of Immunology Research
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-17، 17ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-08-08
دولة النشر
مصر
عدد الصفحات
17
التخصصات الرئيسية
الملخص EN
Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis.
Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC).
However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in clinical practices.
Nowadays, several companion diagnostic assays for PDL1 expression have been introduced for identifying patients who may benefit the immunotherapy.
In addition, results from clinical trials explored combinatory therapeutic strategies with conventional and/or targeted therapy reported a higher efficacy with an acceptable safety profile in NSCLC treatments, as compared to the monotherapy of these agents alone.
In this review article, we summarized several anti-PD-1/PD-L1 agents licensed for NSCLC treatment, with a focus on predictive biomarkers and companion diagnostic assays for identification of NSCLC patients for immunotherapy anti-PD-1/PDL1 antibodies.
Of a great interest, potentials of the combinatory therapy of anti-PD-1/PDL1 therapy with a conventional or targeted therapy, or other immunotherapy such as CAR-T cell therapy were emphasized in the article.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sui, Hongshu& Ma, Ningxia& Wang, Ying& Li, Hui& Liu, Xiaoming& Su, Yanping…[et al.]. 2018. Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-17.
https://search.emarefa.net/detail/BIM-1192906
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sui, Hongshu…[et al.]. Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research No. 2018 (2018), pp.1-17.
https://search.emarefa.net/detail/BIM-1192906
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sui, Hongshu& Ma, Ningxia& Wang, Ying& Li, Hui& Liu, Xiaoming& Su, Yanping…[et al.]. Anti-PD-1PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-17.
https://search.emarefa.net/detail/BIM-1192906
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1192906
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)